Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

HCV NS3 Protease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV (26) HCV Protease (39) Bacterial (1) BCRP (1) Cytochrome P450 (2) Dengue Virus (1) DNA/RNA Synthesis (3) Drug Derivative (1) Endogenous Metabolite (1) Flavivirus (1) Glucocorticoid Receptor (2) Isotope-Labeled Compounds (4) P-glycoprotein (1) Reference Standards (3) SARS-CoV (19)
By Research Areas:	Cancer (3) Infection (43) Inflammation/Immunology (4)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: HCV Protease HCV Virus Protease HIV Protease Protease Activated Receptor (PAR) Ser/Thr Protease ClpP Serpin TMPRSS6 Enteropeptidase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-I0179

ITMN 4077	HCV Protease	Infection
ITMN 4077 is a macrocyclic inhibitor against Hepatitis C Virus (HCV) **NS3 protease (EC₅₀**: 2131 nM) .

HY-12946

BI 653048	Glucocorticoid Receptor Cytochrome P450 HCV Protease	Infection Inflammation/Immunology
BI 653048, a chemical probe, is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC₅₀ value of 55 nM . BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC₅₀>30 μM) . BI 653048 (Compound 103) is also a **HCV NS3 protease** inhibitor that can reduce viral loads infected with the hepatitis C virus .

HY-P2502

*Hepatitis Virus C NS3 Protease* Inhibitor 2**	HCV Protease HCV	Infection
Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a K_i of 41 nM .

HY-16593

GS-9256	HCV Protease	Infection
GS-9256 is a selective **HCV NS3** protease inhibitor. GS-9256 has good pharmacokinetic properties and antiviral activity .

HY-106352

BMS 605339	HCV Protease	Infection
BMS 605339 is a linear tetra-peptide α-ketoamide inhibitor of *HCV* NS3 protease. BMS 605339 can be used in research related to hepatitis C (HCV infection) .

HY-P4035

HCV NS4A Protein (18-40) (JT strain)	HCV	Infection
HCV NS4A Protein (18-40) (JT strain) is an HCV NS4A peptide, which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease .

HY-12946A

BI 653048 phosphate	Glucocorticoid Receptor Cytochrome P450 HCV Protease	Infection Inflammation/Immunology
BI 653048 phosphate is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC₅₀ value of 55 nM . BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC₅₀>30 μM) . BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also a **HCV NS3 protease** inhibitor that can reduce viral loads infected with the hepatitis C virus .

HY-P10608

KK4A peptide	HCV	Infection
KK4A peptide is a small peptide derived from nonstructural protein 4A (NS4A) of hepatitis C virus (HCV) that significantly increases the catalytic efficiency of NS3 protease. The KK4A peptide may be used to gain insights into the function and mechanism of the *HCV* NS3 protease, thereby advancing research into *HCV* infection .

HY-P10657

Ac-DEMEEC-OH	HCV HCV Protease	Infection
Ac-DEMEEC-OH is a **HCV NS3 protease** competitive inhibitor (K_i: 0.6 µM) .

HY-10242

Ciluprevir BILN 2061; BILN 2061ZW	HCV HCV Protease	Infection
Ciluprevir(BILN 2061) is a specific and potent peptidomimetic inhibitor of the **HCV NS3 protease with an IC₅₀** of 3.0 nM.

HY-10243

Vaniprevir MK-7009	HCV HCV Protease	Infection
Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) **NS3/4A protease**.

HY-19840

Voxilaprevir GS-9857	HCV Protease	Infection Cancer
Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of **HCV NS3/4A protease** inhibitor (PI) with pangenotypic antiviral activity . Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with K_i values of 0.038 nM and 0.066 nM, respectively . Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research .

HY-N8520

Variculanol	Bacterial	Infection Cancer
Variculanol is an antimicrobial, anticancer and anti-HCV NS3/4A Protease agent which can be extracted from marine fungus Aspergillus versicolor .

HY-P4039

Ac-EEVVAC-pNA	HCV Protease	Infection
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. The sequence EEVVAC is derived from the 5A-5B cleavage junction of the HCV polyprotein .

HY-10235

Telaprevir Maximum Cited Publications 44 Publications Verification VX-950	HCV Protease HCV SARS-CoV	Infection
Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the **HCV NS3-4A protease, the steady-state inhibitory constant (K_i*) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3* protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-108018

MK 6325	HCV Protease	Infection
MK 6325 is a **HCV NS3/4a protease** inhibitor. MK 6325 displays the broad genotype and mutant potency. MK 6325 can be used for the research of infection .

HY-10235S

Telaprevir-d4 VX-950-d₄	Isotope-Labeled Compounds HCV Protease HCV SARS-CoV	Infection
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-10235R

Telaprevir (Standard) VX-950 (Standard)	Reference Standards HCV Protease HCV SARS-CoV	Infection
Telaprevir (Standard) is the analytical standard of Telaprevir. This product is intended for research and analytical applications. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-126973

BI-1230	HCV Protease	Infection
BI-1230, a chemical probe, is potent and digit nanomolar inhibitor of **HCV NS3 protease and of viral replication*. BI-1230 is also highly selective against other serine/cysteine proteases*. BI-1230 shows good Pharmacokinetic(PK) activity .

HY-17634

Glecaprevir 5+ Cited Publications ABT-493	HCV HCV Protease SARS-CoV	Infection
Glecaprevir is a novel **HCV NS3/4A protease inhibitor, with IC₅₀ values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 4.09 μM .

HY-14434

Asunaprevir 35+ Cited Publications BMS-650032	HCV HCV Protease SARS-CoV	Infection
Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC₅₀ of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-10300

Narlaprevir 5 Publications Verification SCH 900518	HCV HCV Protease SARS-CoV	Infection
Narlaprevir (SCH 900518) is a selective and orally bioavailable **NS3 protease inhibitor with a K_i value of 6 nM and an EC₉₀ value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 2.3 μM .

HY-10238

Danoprevir 15+ Cited Publications ITMN-191; R7227; RO5190591; RG7227	HCV Protease HCV SARS-CoV	Infection
Danoprevir (ITMN-191) is an orally active **NS3/4A protease** inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM) . Danoprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 0.05 μM .

HY-15256A

Faldaprevir sodium BI 201335 sodium	HCV Protease	Infection
Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of **NS3/4A protease** of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection .

HY-17634R

Glecaprevir (Standard)	HCV HCV Protease SARS-CoV	Infection
Glecaprevir (Standard) is the analytical standard of Glecaprevir. This product is intended for research and analytical applications. Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 4.09 μM .

HY-109571

HZ-1157	Flavivirus Dengue Virus HCV Protease	Infection Inflammation/Immunology
HZ-1157 inhibits **HCV NS3/4A protease with an IC₅₀** of 1.0 μmol/L. HZ-1157 (4a) has a high dengue virus inhibitory activity (EC₅₀ = 0.15 μM) and is a relatively nontoxic (CC₅₀ > 10 μM) dengue antiviral agent .

HY-19557

IDX-320	Drug Derivative HCV Protease	Infection
IDX-320 is a Pipecolic acid (HY-Y0669) derivative. IDX-320 inhibits **NS3/4a proteases across genotypes 1a, 1b, 2a, and 4a with an IC₅₀** 0.8-1.9 nM. IDX-320 can be used in the research of HCV infection .

HY-10237

Boceprevir 30+ Cited Publications EBP 520; SCH 503034	HCV Protease HCV SARS-CoV	Infection
Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable **HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀** of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-15256

Faldaprevir BI 201335	HCV Protease	Infection
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of **NS3/4A protease** of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .

HY-10300R

Narlaprevir (Standard) SCH 900518 (Standard)	Reference Standards HCV HCV Protease SARS-CoV	Infection
Narlaprevir (Standard) is the analytical standard of Narlaprevir. This product is intended for research and analytical applications. Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM .

HY-14434R

Asunaprevir (Standard)	HCV HCV Protease SARS-CoV	Infection
Asunaprevir (Standard) is the analytical standard of Asunaprevir. This product is intended for research and analytical applications. Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-P4038

Hepatitis C Virus S5A/5B	HCV Protease	Infection
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructural protein (NS), served as the substrate for the study of HCV NS3 protease activity .

HY-10241

Simeprevir Maximum Cited Publications 44 Publications Verification TMC435; TMC435350	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10241A

Simeprevir sodium TMC435 sodium; TMC435350 sodium	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10237S

Boceprevir-d9 EBP 520-d₉; SCH 503034-d₉	Isotope-Labeled Compounds HCV Protease HCV SARS-CoV	Infection
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CLpro activity .

HY-10237R

Boceprevir (Standard) EBP 520 (Standard); SCH 503034 (Standard)	Reference Standards HCV Protease HCV SARS-CoV	Infection
Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable **HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀** of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-16773

Vedroprevir GS-9451	HCV Protease BCRP P-glycoprotein	Infection
Vedroprevir (GS-9451) is an inhibitor for **HCV NS3/4A protease with an IC₅₀ of 3.2 nM. Vedroprevir is also an inhibitor for breast cancer resistant protein (BCRP) with an IC₅₀ of 1.4 μM. Vedroprevir inhibits P-gp, MRP1 and MRP2 with IC₅₀** of 34, 14.9 and 12 μM, respectively. Vedroprevir exhibits good pharmacokinetic characteristics in rats and dogs .

HY-10241S

Simeprevir-13C,d3 TMC435-¹³C,d₃; TMC435350-¹³C,d₃	Isotope-Labeled Compounds HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-131905S

BMS-986144	Isotope-Labeled Compounds HCV Protease HCV	Infection Inflammation/Immunology Cancer
BMS-986144 is a third-generation, pan-genotype (GT) **NS3/4A protease** inhibitor. BMS-986144 inhibits HCV replicon with EC₅₀s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .

HY-114216

DBPR110	Endogenous Metabolite	Infection
DBPR110 is a nonstructural protein 5A (NS5A) inhibitor with inhibitory activity against hepatitis C virus (HCV). DBPR110 exhibited a 50% effective concentration (EC50) of 3.9 ± 0.9 pM and a selectivity index value of over 12,800,000 by reducing HCV1b replicon reporter expression. DBPR110 also effectively reduced the activity of HCV2a replicon with an EC50 of 228.8 pM and a selectivity index value of over 173,130. DBPR110 showed synergy with interferon alpha (IFN-α), NS3 protease inhibitors, and NS5B polymerase inhibitors. The results of DBPR110 suggest that it may be an effective small molecule inhibitor against HCV NS5A .

HY-12594

Paritaprevir 10+ Cited Publications ABT-450; Veruprevir	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-12594A

Paritaprevir dihydrate ABT-450 dihydrate; Veruprevir dihydrate	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-12594R

Paritaprevir (Standard)	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .

Cat. No.	Product Name	Type

HY-P4039

Ac-EEVVAC-pNA	Chromogenic Substrates
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. The sequence EEVVAC is derived from the 5A-5B cleavage junction of the HCV polyprotein .

Cat. No.	Product Name	Target	Research Area

HY-P5510

Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-(COO)Ala-Ser-Lys(DABCYL)-NH2 HCV NS3 Protease substrate	Peptides	Others
Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-(COO)Ala-Ser-Lys(DABCYL)-NH2 (HCV NS3 protease substrate) is a biological active peptide. (This peptide is a HCV protease substrate incorporating an ester bond between residues P1 and P1. Due to ready transesterification of the scissile bond to the acyl-enzyme intermediate, this substrate shows very high kcat/Km values, enabling detection of activity with subnanomolar nonstructural protein 3 (NS3 protease) concentrations. It is widely used for the continuous assay of NS3 protease activity. Substrate cleavage is proportional to the enzyme concentration with a detection limit for NS3 between 1 nM and 250 pM.

HY-P2502

*Hepatitis Virus C NS3 Protease* Inhibitor 2**	HCV Protease HCV	Infection
Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a K_i of 41 nM .

HY-P4035

HCV NS4A Protein (18-40) (JT strain)	HCV	Infection
HCV NS4A Protein (18-40) (JT strain) is an HCV NS4A peptide, which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease .

HY-P10608

KK4A peptide	HCV	Infection
KK4A peptide is a small peptide derived from nonstructural protein 4A (NS4A) of hepatitis C virus (HCV) that significantly increases the catalytic efficiency of NS3 protease. The KK4A peptide may be used to gain insights into the function and mechanism of the *HCV* NS3 protease, thereby advancing research into *HCV* infection .

HY-P10657

Ac-DEMEEC-OH	HCV HCV Protease	Infection
Ac-DEMEEC-OH is a **HCV NS3 protease** competitive inhibitor (K_i: 0.6 µM) .

HY-P4039

Ac-EEVVAC-pNA	HCV Protease	Infection
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. The sequence EEVVAC is derived from the 5A-5B cleavage junction of the HCV polyprotein .

HY-P4038

Hepatitis C Virus S5A/5B	HCV Protease	Infection
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructural protein (NS), served as the substrate for the study of HCV NS3 protease activity .

Cat. No.	Compare	Product Name	Species	Source

HY-P74898

	NS3 protease Protein, HCV (GST) Hepatitis C virus (HCV-1a) NS3 Protease / helicase immunodominant region Protein ( GST)	Virus	E. coli
	NS3 protease Protein is a zinc-dependent serine protease.NS3 needs to bind to the viral protein NS4A to enable additional conformation changes that enhance activity and appropriate intracellular localization.NS3 protein induces Caspase-8-mediated apoptosis independently of its protease or helicase activity.NS3 protease Protein, HCV (GST) is the recombinant Virus-derived NS3 protease protein, expressed by E.coli , with N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-10237S

Boceprevir-d9
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CLpro activity .

HY-10241S

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-131905S

BMS-986144
BMS-986144 is a third-generation, pan-genotype (GT) **NS3/4A protease** inhibitor. BMS-986144 inhibits HCV replicon with EC₅₀s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HCV NS3 Protease

Inhibitors & Agonists

Fluorescent Dye

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products